Daniel Belew, MD
Urology · Roswell, GANPI 1306229851
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,969 of the $15,698 with a category attached, or 69.9%. It is spread thinly across 53 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2024 at $4,648 and has fallen 58.1% since, to $1,949 in 2025.
Across 345 payments — averaging $45.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- EDAP Technomed Inc$2K
- Coloplast$1K
- Angiodynamics, Inc.$1K
- Teleflex LLC$1K
- Pfizer$378
- plus $6K from 47 others
What the payments were for
- Travel & lodging$4,58729%
- Food & beverage$10,96970%
- Education$1411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$1,046
- Nanoknife$1,035
- TITAN$1,002
- UroLift System$619
- CarePath$278
- GENERAL BPH$264
- AquaBeam Robotic System$156
- UroCuff$154
- REZUM$148
- AMS 700$148
- Optilume BPH Drug Coated Balloon Catheter$147
- Bulkamid$123
- Barrigel$121
- GREENLIGHT$117
- Lupron Depot$112
- UroLift$110
- GENERAL KIDNEY STONE DISEASE$107
- Erleada$105
How this compares
$15,698 in reported general payments places this provider in the 85th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 79 | $1,159,706 |
| XtandiEnzalutamide | 17 | $240,301 |
| MyrbetriqMirabegron | 108 | $99,410 |
| GemtesaVibegron | 37 | $43,878 |
| Tamsulosin Hcl | 391 | $5,844 |
| Estradiol | 48 | $4,225 |
| Tolterodine Tartrate ErTolterodine Tartrate | 38 | $3,812 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 180 | $3,548 |
| Oxybutynin Chloride ErOxybutynin Chloride | 141 | $3,318 |
| Trimethoprim | 18 | $1,585 |
| Finasteride | 118 | $1,517 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 97 | $1,368 |
| Testosterone Cypionate | 35 | $1,095 |
| Silodosin | 12 | $871 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 180 | $680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $178 | $1,159,70679 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $312 | $339,711125 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $76 | $43,87837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 369 urology providers in Georgia.
Other urology in Roswell
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Scott MillerRoswell$85K
- Akash KapadiaRoswell$63K
- Sophia GoodridgeRoswell$18K
- Rutveej PatelRoswell$15K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.